Patents Assigned to Dynavax Technologies Corp.
  • Use of inhibitory oligonucleotides to treat autoimmune disease
    Patent number: 8729039
    Abstract: The invention consists of oligonucleotides which inhibit the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) as well as methods for their identification and use. The oligonucleotides of the invention are useful in controlling therapeutically intended ISS-ODN adjuvant activity as well as undesired ISS-ODN activity exerted by recombinant expression vectors, such as those used for gene therapy and gene immunization. The oligonucleotides of the invention also have anti-inflammatory activity useful in reducing inflammation in response to infection of a host with ISS-ODN containing microbes, in controlling autoimmune disease and in boosting host Th2 type immune responses to an antigen. The invention also encompasses pharmaceutically useful conjugates of the oligonucleotides of the invention (including conjugate partners such as antigens and antibodies).
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 20, 2014
    Assignees: The Regents of the University of California, Dynavax Technologies Corp.
    Inventors: Eyal Raz, Mark Roman
  • Immunostimulatory oligonucleotides with modified bases and methods of use thereof
    Patent number: 6562798
    Abstract: Immunomodulatory oligonucleotide compositions are disclosed. These oligonucleotides comprise an immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in conjunction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: May 13, 2003
    Assignee: Dynavax Technologies Corp.
    Inventor: David Schwartz
  • Inhibitors of DNA immunostimulatory sequence activity
    Patent number: 6225292
    Abstract: The invention consists of oligonucleotides which inhibit the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) as well as methods for their identification and use. The oligonucleotides of the invention are useful in controlling therapeutically intended ISS-ODN adjuvant activity as well as undesired ISS-ODN activity exerted by recombinant expression vectors, such as those used for gene therapy and gene immunization. The oligonucleotides of the invention also have anti-inflammatory activity useful in reducing inflammation in response to infection of a host with ISS-ODN containing microbes, in controlling autoimmune disease and in boosting host Th2 type immune responses to an antigen. The invention also encompasses pharmaceutically useful conjugates of the oligonucleotides of the invention (including conjugate partners such as antigens and antibodies).
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: May 1, 2001
    Assignees: The Regents of the University of California, Dynavax Technologies Corp.
    Inventors: Eyal Raz, Mark Roman